Indazole peptidomimetics as thrombin receptor antagonists

Details Indazole peptidomimetics as thrombin receptor antagonists Indazole peptidomimetics as thrombin receptor antagonists

2006-03-30

2008-08-26

Weber, Jon (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S018700, C514S385000, C514S403000, C530S330000, C530S331000, C548S146000, C548S215000, C548S305700, C548S333500

Reexamination Certificate

active

07417030

ABSTRACT:
The invention is directed to novel indazole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indazole peptidomimetics of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.

REFERENCES:
patent: 6365617 (2002-04-01), McComsey et al.
patent: 6630451 (2003-10-01), Zhang et al.
patent: 6858577 (2005-02-01), Zhang et al.
patent: 7049297 (2006-05-01), Zhang et al.
Cheseboro et al, “Antithrombotic Therapy and Progression of Coronary Artery Disease,” CIRCULATION, 1992, pp. 100-110, vol. 86, No. 6[Supp III].
Verstraete et al, “Novel Antithrombotic Drugs in Development,” DRUGS, 1995, pp. 856-884, vol. 49.
White, Harvey D., “Newer antiplatelet agents in acute coronary syndromes,” J. Am Heart, 1999, pp. S570-S576, vol. 138.
Weksler, Babette B., “Antiplatelet Agents in Stroke Prevention,” Cerebrovascular Diseases, 2000, pp. 41-48, vol. 10 (suppl 5).
Mousa et al, “Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond,” Drug Discovery Today, 1999, pp. 552-561, vol. 4.
Andrade-Gordon et al, “Administration of a Potent Antagonist of Protease-Activated Receptor-1 (PAR-1) Attenuates Vascular Restenosis Following Balloon Angioplasty in Rats,” J Pharmacol Exp Ther, 2001, pp. 34-42, vol. 298, No. 1, USA.
Derian et al, “Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates,” J Pharmacol Exp., 2003, pp. 855-861, vol. 304, No. 2, USA.
Linde et al, “Pharmacological treatment for prevention of restenosis,” Expert Opin Emerging Drugs, 2001, pp. 281-301, vol. 6, Ashley Publications.
Ischinger, Thomas, MD., “Antithrombotics in Interventional Cardiology; Optimizing Treatment and Strategies,”, J Amer Cardiol, 1998, pp. 25L-28L, vol. 82, Excerpta Medica, Inc.
Schwartz, Robert S., “Pathophysiology of Restenosis: Interaction of Thrombosis, Hyperplasia, and/or Remodeling,”, Am J Cardiol, 1998, pp. 14E-17E, vol. 81, Excerpta Medica, Inc.
Marx et al, “Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells,”, Circ Res., 1995, pp. 412-417, vol. 76, American Heart Association, Inc.
Sollott et al, “Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat,”, The Journal of Clinical Invest., Inc., 1995, pp. 1869-1876, vol. 95.
Suzuki et al, “Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model,” Circulation, 2001, pp. 1188-1193, vol. 104.

Affiliated with

Also associated with

Rating

Indazole peptidomimetics as thrombin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Indazole peptidomimetics as thrombin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indazole peptidomimetics as thrombin receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4019552